Thailand

The primary regulatory authority for health products in Thailand is the Food and Drug Administration (Thai FDA), operating under the Ministry of Public Health (MOPH). The Thai FDA governs the registration, licensing, and post-market surveillance of pharmaceuticals, medical devices, diagnostics, and digital health solutions through a framework of product-specific legislation, including the Drug Act B.E. 2510 (1967) and its amendments, the Medical Device Act B.E. 2562 (2019), and relevant ministerial notifications. All health products intended for the Thai market must obtain product registration or notification approval from the Thai FDA before import, manufacture, or sale. The approval pathway varies by product risk classification, with higher-risk products subject to more rigorous pre-market review, while lower-risk products may qualify for notification or abbreviated review tracks. Thailand is a member of the ASEAN Harmonization Initiative, and the Thai FDA participates in ASEAN Medical Device Directive (AMDD) and pharmaceutical harmonization efforts, which increasingly shape domestic review standards.

Key submission requirements include the appointment of a locally registered importer or manufacturer as the legal applicant, as foreign entities cannot apply directly for product registration. Dossiers are generally expected to follow the ASEAN Common Technical Dossier (ACTD) format for pharmaceuticals, while medical device submissions align with the ASEAN Medical Device Dossier (AMDD) framework. The Thai FDA has accelerated adoption of its e-submission platform, known as the SKYNET system, to streamline registration workflows. Notable recent reforms include the enactment of the Medical Device Act B.E. 2562, which introduced a formal four-tier risk-classification system and established new conformity assessment and post-market surveillance obligations. The Thai FDA has also implemented a fast-track review pathway for innovative, essential, or nationally prioritized health products, reducing timelines for qualifying submissions. Regulatory reliance mechanisms, drawing on approvals from recognized reference agencies such as the US FDA, EMA, and TGA, are increasingly available for certain product categories.

Public procurement of health products in Thailand is centrally anchored within the Ministry of Public Health, which oversees a national network of government hospitals, district health offices, and primary care units. The Government Pharmaceutical Organization (GPO), a state enterprise under the MOPH, plays a dual role as both a domestic manufacturer and a central procurement agency for pharmaceuticals and selected medical supplies, supplying public health facilities at negotiated prices. Large-scale national tenders for pharmaceuticals and medical devices are coordinated through the MOPH's Central Procurement Unit, while individual public hospitals and regional health authorities retain authority to conduct their own procurement for items outside centrally listed contracts. The National Health Security Office (NHSO), which administers the Universal Health Coverage (UHC) scheme, significantly influences procurement priorities by maintaining a national essential medicines list and a benefits package that guides formulary and device access decisions across public facilities. The Government Procurement and Supplies Administration Act B.E. 2560 (2017) governs public sector purchasing procedures, emphasizing transparency, competitive bidding, and electronic tendering through the GEPS platform.

The private sector constitutes a substantial and growing channel for health product commercialization in Thailand, encompassing a network of private hospitals, retail pharmacy chains, and specialty clinics that procure independently through distributors and direct supplier agreements. Private sector pricing and access decisions are largely market-driven, though the MOPH retains oversight of retail price controls for certain essential medicines. Thailand has a strong domestic pharmaceutical and medical device manufacturing industry, and government policy actively encourages local production through preferential procurement margins for locally manufactured products under the MOPH's localization and self-sufficiency frameworks. Donor-funded procurement channels, including those managed by UNICEF, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and USAID, have historically played a limited but targeted role in Thailand, primarily supporting specific disease programs such as HIV and tuberculosis. As an upper-middle-income country, Thailand has transitioned away from major external donor dependency for health commodities, though technical collaboration with international agencies continues to inform procurement standards and supply chain strengthening initiatives.